Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
8.71
+0.09 (1.04%)
Jul 30, 2025, 12:09 PM - Market open

Company Description

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.

The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals logo
CountryUnited States
Founded2018
IPO DateOct 25, 2019
IndustryBiotechnology
SectorHealthcare
Employees427
CEOSteven Basta

Contact Details

Address:
100 Campus Drive, Suite 102
Florham Park, New Jersey 07932
United States
Phone877 742 8466
Websitephathompharma.com

Stock Details

Ticker SymbolPHAT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$19.00
CIK Code0001783183
CUSIP Number71722W107
ISIN NumberUS71722W1071
Employer ID82-4151574
SIC Code2834

Key Executives

NamePosition
Steven L. Basta M.B.A.Chief Executive Officer, President and Director
David A. SocksCo-Founder
Dr. Azmi Nabulsi M.D., M.P.H.Co-Founder
Robert BreedloveVice President of Finance and Principal Accounting Officer
Jonathan BentleySenior Vice President and Head of Sales, Operations and Training
Bill Aprea J.D.Senior Vice President, Chief Compliance Officer and Deputy Chief Legal Officer
Anne Marie Cook Esq., J.D.Chief Legal Officer and Corporate Secretary
Susan KimSenior Vice President of Marketing
Paul CocjaChief People Officer
Dr. Eckhard Leifke M.D., Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jun 16, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report
Jun 9, 2025SCHEDULE 13G/AFiling
Jun 6, 20258-KCurrent Report
Jun 6, 2025SCHEDULE 13G/AFiling
Jun 4, 2025SCHEDULE 13G/AFiling
May 13, 2025SCHEDULE 13D/AFiling
May 1, 202510-QQuarterly Report
May 1, 20258-KCurrent Report
Apr 24, 2025SCHEDULE 13G/AFiling